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Time to detection of Mycobacterium tuberculosis in broth culture was examined for utility as a treatment
efficacy end point. Of 146 patients in a phase IIB trial, a decreased mean time to detection was found in 5 with
treatment failure. Time to detection in an analysis-of-covariance model was associated with lung cavities, less
intensive treatment, and differences in the bactericidal effects of treatment regimens.
Development of new treatments for tuberculosis is ham-
pered by the lack of an accurate surrogate end point and the
high degree of efficacy of current 6-month regimens. Sputum
culture status after 2 months of therapy, a binary test, is widely
used for phase IIB trials but has only moderate accuracy for
predicting failure/relapse (12) and requires large sample sizes
(4, 8). Changes in the number of colonies found in dilutions of
sputum applied to solid medium is an end point that has been
used to assess activities of single drugs and doses in phase IIA
(early-bactericidal-activity) studies (10) and has also been sug-
gested as an end point for phase IIB trials (15). Though prom-
ising, quantitative culture on solid medium involves prolonged
sputum collections and intensive laboratory techniques and has
been difficult to standardize at multiple sites. Time to detection
in broth culture (TTD) is a potential end point that has a good
correlation with quantitative culture on solid medium (11, 13).
An initial small study had suggested a correlation between a
shorter time to detection (an indication of higher numbers of
viable bacilli) and poor treatment outcomes (9). In this study,
TTD was evaluated as a marker of regimen potency. Prelimi-
nary results have been reported elsewhere (16).
MATERIALS AND METHODS
Experimental design. Patients for this study were drawn from Tuberculosis
Trials Consortium (TBTC) Study 27, a randomized phase IIB trial that compared
moxifloxacin to ethambutol and treatment 5 versus 3 times per week during the
initial 2 months of treatment among patients with smear-positive, pulmonary
tuberculosis (4). After completion of intensive-phase therapy, patients received
standard continuation-phase treatment (3). The primary end point of the treat-
ment trial was the dichotomous end point of 2-month culture status.
For this post hoc study, TTD data were available from two African sites. Of 176
African patients in study 27, TTD data were available for 163 (93%). Treatment
failure occurred in six of these patients, and although the patients were not
routinely followed after therapy, one with a relapse was identified 5 weeks after
treatment.
Specimen collection and laboratory procedures. Spontaneously expectorated
(spot) sputum samples were cultured every 2 weeks during the first 2 months and
monthly thereafter. Standard culture methods were used but differed somewhat
between sites. In Uganda, samples were processed using a final concentration of
1% sodium hydroxide, inoculated into Bactec 12B bottles, and monitored with
the Bactec 460 system. In South Africa, a final concentration of 1.25% sodium
hydroxide, MGIT broth, and the Bactec MGIT 960 instrument were used. Cul-
tures were monitored daily at both sites, with the exception that after 2 weeks,
the Bactec 460 protocol used daily monitoring for cultures with a Bactec growth
index (GI) of 30 and once weekly for cultures with a GI of 30 (no. 444824;
Bactec TB System Product & Procedure Manual; Becton Dickinson). TTD was
calculated as the number of days between inoculation and detection of a positive
culture by the Bactec instruments; the results for specimens not positive by the
end of the monitored interval were recorded as 42 days. Most patients had two
sputum specimens cultured at each time point. The result of the first culture for
each patient and time point was used, with two exceptions. If the first culture was
contaminated with bacteria or grew nontuberculosis mycobacteria (NTM), the
second culture was used.
Data analysis. The primary objective of this analysis was to compare micro-
biological end points for predicting treatment failure by TTD and by 2-month
culture status. We used test cutoffs for the TTD end point that identified all
patients with treatment failure (sensitivity, 100%). The accuracy of the test was
calculated as the number of true-positive patients plus the number of true-
* Corresponding author. Mailing address: VAMC, Division of In-
fectious Diseases (111), 7400 Merton Minter Blvd., San Antonio TX
78229-4404. Phone: (210) 617-5300, ext. 16060. Fax: (210) 617-5297.
E-mail: weiner@uthscsa.edu.
 Published ahead of print on 6 October 2010.













negative patients for treatment failure with tuberculosis divided by the number
of true-positive, false-positive, true-negative, plus false-negative patients.
Data analyses were performed using the SAS program (version 9.1) for the
mixed-model analysis of covariance (ANCOVA) and generalized estimating
equations (GEE), the StatXact program for nonparametric tests, and the NCSS
2007 program for other tests. For binary data, differences between groups were
determined using Fisher’s exact test or Pearson’s chi-square statistic, and for
nonparametric analyses, the Kruskal-Wallis test by the Monte Carlo method was
used. Arithmetic means (see Table 1 and Fig. 2) and adjusted means with the
ANCOVA model (see Table 4 and Fig. 3) were used where applicable. Differ-
ences between groups were considered statistically significant at the level of a P
value of 0.05.
We also evaluated the effect of TTD with clinical and radiographic factors and
the randomized study arms. Initially, univariate analysis of each factor, adjusted
for missing data (TTD at weeks 2, 4, 6, and 8), was performed. A mixed-model
ANCOVA with repeated measures was then evaluated. In the final model, main
effects were cavity (absent, 4 cm in total size, 4 cm in total size), HIV
infection status (infected or not infected), drug (moxifloxacin versus ethambu-
tol), frequency of study treatment (5 versus 3 times per week), site (Uganda or
South Africa), baseline TTD, the repeated measure (2, 4, 6, and 8 weeks), and
the two-way interactions of the main effects (with the exceptions of study site and
the baseline culture). Because of the model’s complexity, a parsimonious ap-
proach with elimination of nonsignificant higher-level interactions was adopted.
Of the 163 patients, 158 patients had complete data for independent factors and
baseline TTD (Fig. 1). Homogeneity of variance was supported by plotting of
residuals versus predicted values. Adjusted means refers to means adjusted for
all model effects, unequal sample sizes, and missing data among the repeated
measures. The model takes into account the intrasubject correlation of repeated
sampling; serial correlation was estimated to be small, with R2 being 0.05. The
significance of pairwise comparisons is reported using Fisher’s least significant
difference (LSD).
We also performed an alternate GEE analysis with cultures identified as
TABLE 1. Comparison of demographic, clinical, and radiographic characteristics of patients in study 27
who were part or not part of this substudy
Characteristic
Study 27
P valuePatients in this
studya
Patients not in this
studyb
Median (IQRc) age (yr) 29 (23.3–36.0) 36 (26.3–49.8) 0.001
No. of patients male/total no. of patients (% male) 99/163 (61) 87/115 (76) 0.01
Race/ethnicityd
African 163/163 (100) 13/115 (11) 0.001
Black 162/163 (99) 46/115 (49) 0.001
Hispanic 0/163 (0) 39/115 (34) 0.001
White 0/163 (0) 45/115 (39) 0.001
Asian 1/163 (1) 19/115 (17) 0.001
Median (IQR) wt (kg) 52.4 (47.1–57.1) 58.6 (53.9–66.5) 0.001
Chest radiographic featuresd
Cavitation 133/163 (82) 73/115 (64) 0.001
Bilateral involvement 103/161 (64) 56/102 (55) 0.16
HIV infectedd 43/163 (26) 18/114 (16) 0.04
Median (IQR) CD4 cell count (l1) in HIV-infected patients 200 (110–286) 189 (85–335) 0.97
Patients for whom moxifloxacin was used as study drugd 81/163 (50) 58/115 (50) 1.00
a n  163 (59%).
b n  115 (41%).
c IQR, interquartile range.
d Data represent number of patients with the indicated characteristic/total number of patients in group (percent).
FIG. 1. Flow of patients into the end point study of TTD.
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positive or negative for M. tuberculosis and compared the results with those of the
comparable ANCOVA model.
In this model, TTDs of 1 to 41 days were scored positive and a TTD of 42 was
scored negative. Because of the small sample size for one of the three cavity
levels (4 cm), cavity was collapsed to a binomial response. Adjusted propor-
tions refer to the proportions adjusted for all model effects, unequal sample sizes,
and missing data among the repeated measures.
RESULTS
Patients. Of 163 patients, 147 (90%) were enrolled in
Uganda and 16 (10%) were enrolled in South Africa. Com-
pared to patients enrolled in the original clinical trial who were
not included, patients in this substudy were significantly
younger, more often male and of black race, weighed less, and
were more likely to be HIV infected (Table 1). The median
baseline CD4 cell count of HIV-infected subjects in the sub-
study was 200 l1 (range, 110 to 286 l1).
Culture end points and treatment failure. Of 163 patients
with TTD culture results, 146 patients, including 5 of the 6
patients with failure, had data for four cultures in the 2 months
of study therapy. In these 146 patients, there was more rapid
detection of growth (TTD of four cultures) in the five patients
who failed treatment than in the others who did not fail treat-
ment (mean  standard deviation, 16.3  2.9 days [range, 13.0
to 20.3 days] versus 25.4  6.7 days [range, 6.0 to 42.0 days];
P  0.003 by t test) (Tables 2 and 3 and Fig. 2). When TTD was
assessed as a diagnostic end point for treatment failure, using
a mean cutoff of less than 21 days (for specimens for culture
obtained 2, 4, 6, and 8 weeks after the beginning of study
treatment), the accuracy was 75%, the sensitivity was 100%,
the specificity was 74%, the positive predictive value (PPV)
was 12%, and the negative predictive value (NPV) was 100%
(Table 3, end point label 1). Improved PPVs (18 to 20%) and
similar sensitivities and specificities were obtained when fewer
time points were used (two time points at week 6 and 8 cultures
or one time point at week 8 culture) (Table 3, end point labels
2 and 3). By comparison, the alternative end point of culture
conversion to negative after 2 months of treatment was less
accurate and specific (accuracy, 47%; sensitivity, 100%; spec-
ificity, 49%; positive predictive value, 6%; negative predictive
value, 100; Table 3, end point label 4).
Among 38 HIV-infected patients at initial testing, 7 (18%)
had cavitary lung disease, received ethambutol, and were on
intermittent therapy; 4 of the 7 (57%) had treatment failure.
The accuracy of the TTD end point (four time points with a
mean of 21 days) among the 24 HIV-infected patients with
cavitary disease was 71% (sensitivity, 100%; specificity, 65%;
PPV, 36%; NPV, 100%).
Correlation of TTD with known risk factors for combined
end point of treatment failure and relapse. Significant effects of
TTD in univariate analysis were also found in multivariate
ANCOVA (Table 4). TTD was associated with cavitary lung
disease; i.e., the greatest decrease (delayed response) was with
large cavities, an intermediate decrease was with small cavities,
and the lowest decrease was without cavities (Table 4; Fig. 3). The
adjusted mean TTD was also significantly decreased among pa-
tients treated thrice weekly and with ethambutol (versus moxi-
TABLE 3. Range of sensitivity, specificity, positive and negative predictive values, and accuracy of mean TTD with different numbers































1 2, 4, 6, 8 146 5 100 74 12 100 75 21 0.003e
2 6, 8 151 6 100 83 20 100 76 22 0.001e
3 8 158 6 100 82 18 100 77 23 0.001e
Two-month culture
conversion, 4
8 146 5 100 49 6 100 47 —f 0.03g
a Five of six patients with tuberculosis failure had four TTD cultures results.
b Cutoff chosen to achieve sensitivity of 100%.
c (Number of true-positive cases  number of true negative cases)/all cases.
d The test was positive if the mean TTD was 21 days for the mean of four time points, 22 days for the mean for two time points at weeks 6 and 8, and 23 days
if only the week 8 TTD was evaluated.
e P by t test of treatment failure versus others.
f —, test positive if 2-month culture was positive for M. tuberculosis.
g P value by Fisher’s exact test.
FIG. 2. Patients with (Œ, n  5) and without (ƒ, n  133) treat-
ment failure (all with four time points, relapse case excluded). Unad-
justed means (bars, 95% confidence intervals) of time to detection are
depicted on the y axis; the week of study treatment when sputum for
was culture obtained is depicted on the x axis.
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floxacin). By comparison, 2-month culture conversion rates were
similar among 158 patients treated thrice weekly versus 5 days/
week (46% versus 51% culture conversion; P  0.5, chi-square
test) or treated with moxifloxacin versus ethambutol (culture con-
version, 54% versus 46%; P  0.42). Although not significant, the
direction of proportions with 2-month culture conversion corre-
sponded to the significant differences observed with TTD.
Other analyses of TTD. The adjusted mean TTD differed
between study sites (Uganda versus South Africa, 25.5 days
versus 20.8 days; P  0.008), reflecting in part differences
among patient groups and in the culture processing methods,
the broth media, and the monitoring methodologies used.
However, differences in the adjusted mean TTD of other co-
factors were similar between models of Ugandan patients
alone and all patients (Uganda and South Africa). Further,
there were no significant differences by site between drugs or
treatment frequency; i.e., there were no site interactions.
These findings are consistent with an increase in power from a
larger sample size with all patients.
From 161 patients, 591 duplicate sputum cultures (of spec-
imens obtained from the baseline to week 8 of treatment) with
TABLE 4. Univariate and multivariate effects on TTDa
Factor or covariate DFb




P value F value TTD adjustedmean (days) P value
Drug
Moxifloxacin 1 27.4 0.01 5.1 24.5 0.026
Ethambutol 24.5 21.9
Cavity
None 2 28.4 0.015 6.2 27.1 0.003
4 cm 26.0 23.7
4 cm 22.7 18.6
Frequency of treatment per wk
3 times 1 25.4 0.26 4.2 22.0 0.042
5 times 26.3 24.3
Site
Uganda (Bactec) 1 26.3 0.038 7.28 25.5 0.008
South Africa (MGIT) 22.3 20.8
HIV infection status
Infected 1 25.8 0.88 0.0 23.1 0.97
Not infected 26.0 23.2
Duration of study treatment (wk)




Baseline culture (covariate of TTD) 1 19.1 .001
Interaction
Cavity by HIV infection status 2 5.3 0.006
Cavity by duration of treatment 6 2.8 0.013
HIV infection status by frequency
of treatment per wk
1 4.5 0.036
a In the multivariate mixed-effect ANCOVA model, all the main effects and interactions with a P value of 0.05 are shown.
b DF, numerator degrees of freedom; n  158.
c Not adjusted for other main effects or interaction of effects from the final model but adjusted for missing data on the repeated measure (TTD at weeks 2, 4, 6, and 8).
FIG. 3. Growth was detected sooner in patients with large cavities
and was intermediate in those with small cavities than in patients
without cavities (ƒ, with cavity of 4 cm; E, with cavity of 4 cm) or
no cavity (Œ), with the adjusted mean (standard error [SE], bars) TTD
(y axis) being plotted versus week of treatment (x axis).
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results of Mycobacterium tuberculosis or no growth were evalu-
able. TTDs in the duplicate cultures were significantly corre-
lated (P  0.0001, R2  0.69).
Other analyses of the TTD data were performed to explore
the operating characteristics of the ANCOVA model. A fre-
quency distribution of TTD data from 1 to 41 days demon-
strated a middle peak and two tails with very low frequencies
at days 1 and 2 and days 39, 40, and 41. Because about 30% of
cultures did not demonstrate growth by the end of the moni-
tored interval, we performed a sensitivity analysis of the effect
of censoring at 42 days. Model term estimates and the signif-
icance of terms were insensitive to imputed censoring at 39 or
at 45 days compared to 42 days.
We also performed GEE analysis to evaluate the effect of
scoring all cultures as either positive or negative and compared
the results to those obtained with a parallel TTD ANCOVA
model. The significance of model terms and the direction of
change between model terms were comparable between the dif-
ferent models, with one substantive exception (Table 5). The
adjusted mean TTD of site differed significantly in the ANCOVA
model but not in the GEE model. This demonstrates the similar-
ity of data from the Bactec system, used at the Uganda site, and
the MGIT system, used in South Africa, when culture results are
analyzed as binary positive or negative results. However, a differ-
ence is distinguished between the monitoring systems with TTD
data, likely reflecting the greater sensitivity of MGIT medium and
monitoring to detect M. tuberculosis.
DISCUSSION
Identification of an accurate surrogate end point of treat-
ment efficacy will advance trial design and development of new












Moxifloxacin 26.1 0.004 0.33 0.06
Ethambutol 24.1 0.22
Cavity
Present 23.5 0.001 0.18 0.02
None 27.3 0.38
Frequency of treatment per wk
3 times 24.0 0.002 0.20 0.02
5 times 26.8 0.36
Site
Uganda 27.4 0.006 0.24 0.57
South Africa 23.4 0.30
HIV infection status
Infected 26.7 0.02 0.36 0.03
Uninfected 24.1 0.20





Baseline culture (covariate of TTD) 0.001 0.001
Interaction
Frequency of treatment per wk by HIV infections status 0.004 0.03
3 times for HIV-positive patients 24.0 0.21
5 times for HIV-positive patients 29.4 0.54
3 times for HIV-negative patients 24.2 0.19
5 times for HIV-negative patients 24.2 0.21
Cavity by HIV infection status 0.001 0.001
Positive cavity for HIV-positive patients 22.7 0.16
Negative cavity for HIV-positive patients 30.6 0.61
Positive cavity for HIV-negative patients 24.2 0.21
Negative cavity for HIV-negative patients 24.0 0.19
Cavity by duration of study treatment 0.06 0.35
a All main effects and interactions with a P value of 0.05 are shown.
b Probability of a negative culture adjusted for all other effects in the model.
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antituberculosis drugs and regimens. In this study, TTD of
growth appeared to be a promising end point for phase IIB
trials because it identified patients who went on to treatment
failure more accurately than 2-month culture status. Moreover,
TTD was correlated with the most consistent risk factor for
treatment failure or relapse: the presence and extent of pul-
monary cavitation (1, 2, 4, 6, 7, 8). Finally, TTD appeared to be
a more sensitive measure of differences between the random-
ized treatment arms than 2-month culture status, suggesting
the greater activity of more frequent dosing and of moxifloxa-
cin-based regimens than of ethambutol-based regimens. The
efficacies of these treatment interventions have been demon-
strated in prior studies (5, 7, 14). Notably, in our study, these
differences were shown with a relatively small sample size
(about 40 patients for each of four treatment arms) and with
spot sputum sample collection (rather than prolonged sputum
sample collection). Thus, the TTD end point may be valuable
in exploring the pharmacodynamics of moxifloxacin and ri-
fampin therapy (17).
Our study has several limitations. Broth cultures were per-
formed according to the manufacturer’s specifications and
TTD was adjusted between sites, but we did not standardize
laboratory processing or monitoring techniques. That we were
able to identify cases of treatment failure and detect differ-
ences among the four treatment groups is, therefore, all the
more notable. Residual confounding by other (unmeasured)
differences among sites is possible. However, we found no
interaction of site with study drug, frequency of treatment, or
other clinical factors. The effect of censoring cultures at 42
days appeared to be small because differences in adjusted
mean estimates of TTD and significance (P) values were sim-
ilar between the final model with censoring set at 42 days and
other models with censoring set at 39 or 45 days. Further,
results were comparable in GEE analysis when all culture
results were scored as either positive or negative. Finally, be-
cause the original trial was a phase II study, patients were not
followed for relapse. However, a disease continuum between
treatment failure and relapse was suggested, in that five of six
cases of treatment failure in this study were detected in (more
sensitive) liquid broth culture after 4 months of therapy but not
in concurrent cultures on solid media.
In summary, TTD identified treatment failure more accu-
rately than 2-month culture status and differentiated among
treatment groups, suggesting superior bactericidal activity with
more frequent dosing and with moxifloxacin. These findings
support further evaluation of the utility of the TTD end point
in treatment trials.
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